戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  required for glycine receptor inhibition by ginkgolides.
2 pha1beta2 and alpha1beta2gamma2 receptors to ginkgolides.
3 onally, the antioxidants ginsenoside Rb1 and ginkgolide A effectively reversed HAART drug-induced vas
4 modulating Abeta oligomeric species, and (3) ginkgolide A has therapeutic potential for prevention an
5 ss is not the mechanism by which EGb 761 and ginkgolide A suppress Abeta-induced paralysis because th
6 port that EGb 761 and one of its components, ginkgolide A, alleviates Abeta-induced pathological beha
7 s pioglitazone, levonorgestrel, salsolidine, ginkgolide A, and icariin).
8         In parallel, the formal syntheses of ginkgolides A (1) and B (2) were accomplished via interc
9         These acetyl derivatives, as well as ginkgolides A and B acetates have been investigated for
10  of ginkgolide C and the formal syntheses of ginkgolides A and B.
11                                         Both ginkgolides and bilobalide inhibit GABA(A) receptors, wi
12                         Terpene trilactones (ginkgolides and bilobalide) are unique constituents of G
13                     Their active components (ginkgolides and bilobalide) have structures similar to t
14              The terpene trilactones (TTLs), ginkgolides and bilobalide, are structurally unique cons
15 t of specialized metabolites, in particular, ginkgolides and bilobalide, which are chemically complex
16 nd demonstrate a striking similarity between ginkgolides and picrotoxinin, a GABA(A) and recombinant
17 emonstrates a strong interaction between the ginkgolides and the 2' residue, a result supported by in
18                                              Ginkgolides are diterpenes isolated from Ginkgo biloba t
19                                              Ginkgolides are highly oxygenated diterpenes isolated fr
20                                              Ginkgolides are known antagonists of the platelet-activa
21                     We find that most of the ginkgolides are selective and potent antagonists of the
22                                              Ginkgolides are structurally unique constituents of Gink
23 n with the PAF inhibitors WEB 2086 (WEB) and ginkgolide B (GB).
24 sigargin (TPG, 3), andrographolide (AGL, 4), ginkgolide B (GKL B, 5), jolkinolide B (JKL B, 6), nagil
25     Ginkgolide C is 25-fold less potent than ginkgolide B as a PAF receptor antagonist, due to the pr
26 ein we describe the synthesis of a series of ginkgolide B derivatives with modifications at the 7-pos
27 thermore, standard reduction of 7alpha-azido ginkgolide B did not give the expected primary amine, bu
28 es nucleophilic attack on a 7beta-O-triflate ginkgolide B did not lead to the expected products, but
29 d PAF receptor, confirming that of the TTLs, ginkgolide B is the most potent PAF receptor antagonist.
30 7alpha-fluoro ginkgolide B was equipotent to ginkgolide B underlining the critical importance of the
31        Recently, we found that 7alpha-fluoro ginkgolide B was equipotent to ginkgolide B underlining
32                    Conversely, vitamin C and ginkgolide B were not efficient quenchers of singlet oxy
33 tivating factor receptor (PafR) antibody and Ginkgolide B, a well-defined PafR antagonist, demonstrat
34 ta-substituents, in particular 7alpha-chloro ginkgolide B, the most potent nonaromatic ginkgolide der
35 antibodies against PAFR and PAFR antagonist, ginkgolide B.
36 locked when platelets were preincubated with Ginkgolide B.
37 harmacologically active terpene trilactones (ginkgolides, bilobalide) from the tissues of Ginkgo bilo
38 sion analysis to reveal the primary steps in ginkgolide biosynthesis.
39                                              Ginkgolides, but not vitamin E, inhibited the Abeta-indu
40 rein, we report the first total synthesis of ginkgolide C (3), the most structurally complex member o
41 hese acetylations have given rise to various ginkgolide C acetates and iso-ginkgolide C acetates, the
42 ise to various ginkgolide C acetates and iso-ginkgolide C acetates, the latter having a rearranged sk
43 in, we reported the first total synthesis of ginkgolide C and the formal syntheses of ginkgolides A a
44 ective acetylation of the hydroxyl groups of ginkgolide C have been developed.
45                                              Ginkgolide C is 25-fold less potent than ginkgolide B as
46 The highly complex molecular architecture of ginkgolides, combined with their remarkable biological p
47 ro ginkgolide B, the most potent nonaromatic ginkgolide derivative described to date with a K(i) valu
48                                              Ginkgolide derivatives carrying photoactivatable and flu
49                                              Ginkgolide derivatives incorporating both fluorescent an
50                These studies have shown that ginkgolide derivatives with aromatic photoactivatable su
51 products, but gave rise to two unprecedented ginkgolide derivatives, one with a novel rearranged skel
52 unified synthetic platform for accessing the ginkgolide family and offers new opportunities for the s
53 the critical importance of the 7-position of ginkgolides for PAF receptor activity.
54                                         Four ginkgolides (GA, GB, GC, GJ) and bilobalide (BB) from bo
55                  Our work uncovers the early ginkgolide pathway and offers a glance into the biosynth
56 e GABA(A) receptor alpha-subunits, decreases ginkgolide potency by up to 10,000-fold.
57 icable to G. biloba congeners, including the ginkgolides-some of which are glycine-receptor-selective
58      Pretreatment of the cells with isolated ginkgolides, the anti-oxidant component of Ginkgo biloba
59 ellent ligands for clarifying the binding of ginkgolides to PAF receptor by photolabeling studies.
60  strategy guided by the compact structure of ginkgolide, where a series of diastereoselective carbon-
61 esting with cloned PAF receptors showed that ginkgolides with 7alpha-substitutents had increased affi